当前位置：
X-MOL 学术
›
JACC Heart Fail.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Utility of Biomarkers in Cardiac Amyloidosis.
JACC: Heart Failure ( IF 10.3 ) Pub Date : 2020-07-08 , DOI: 10.1016/j.jchf.2020.03.007 Arianna Pregenzer-Wenzler 1 , Jo Abraham 1 , Kelsey Barrell 1 , Tibor Kovacsovics 2 , Jose Nativi-Nicolau 1
中文翻译：
生物标志物在心脏淀粉样变性中的应用。
更新日期：2020-09-01
JACC: Heart Failure ( IF 10.3 ) Pub Date : 2020-07-08 , DOI: 10.1016/j.jchf.2020.03.007 Arianna Pregenzer-Wenzler 1 , Jo Abraham 1 , Kelsey Barrell 1 , Tibor Kovacsovics 2 , Jose Nativi-Nicolau 1
Affiliation
|
Cardiac amyloidosis is a growing field, with advancements in diagnosis and management. Cardiac biomarkers are used to predict survival and to develop severity staging systems. Cardiac biomarkers are also used in clinical practice to stratify patients for treatment and to evaluate response to therapies. The current review summarizes the major clinical utility of current biomarkers in patients with cardiac amyloidosis and provides insights about future areas of investigation.
中文翻译：
生物标志物在心脏淀粉样变性中的应用。
随着诊断和管理的进步，心脏淀粉样变性是一个不断发展的领域。心脏生物标志物用于预测生存和开发严重程度分期系统。心脏生物标志物还用于临床实践中对患者进行分层治疗并评估对治疗的反应。本综述总结了当前生物标志物在心脏淀粉样变性患者中的主要临床效用，并提供了有关未来研究领域的见解。
京公网安备 11010802027423号